>
  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Seropositive Rheumatoid Arthritis Drug Market Research Report Information By Drug Class (Nsaid, Dmards, Biologics), Treatment (Synovectomy, Tendon Repair, Joint Fusion), Diagnosis, Drug, Application, Route Of Administration, End User – Global Forecast Till 2032


ID: MRFR/Pharma/4123-HCR | 90 Pages | Author: Rahul Gotadki| November 2024

Seropositive Rheumatoid Arthritis Drug Market Overview


Seropositive Rheumatoid Arthritis Drug Market Size was valued at USD 1.62 Billion in 2023. The Global Seropositive Rheumatoid Arthritis Drug industry is projected to grow from USD 1.83 Billion in 2024 to USD 5.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.78% during the forecast period (2024 - 2032). Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in the hands and feet.


Seropositive Rheumatoid Arthritis Drug Market


There are two types of rheumatoid arthritis are seronegative rheumatoid arthritis and seropositive rheumatoid arthritis. Smoking and family history are considered as some of the major cause of rheumatoid arthritis.


The rising R&D of product pipeline along with the introduction of novel products are some of the major trends in this market. For instance, in February 2016, Pfizer received FDA approval for commercialization of XELJANZ XR (tofacitinib citrate) in the U.S. market. The company launched the product in Europe for the treatment of rheumatoid arthritis. In May 2017, Sanofi received FDA approval for Kevzara drug for its commercialization in the U.S. market. Kevzara is used in the treatment of active rheumatoid arthritis.


The seropositive rheumatoid arthritis drug market is expected to be driven by factors such as rising cigarette consumption, growing healthcare expenditure, increasing female population, and increasing obese population. However, the growth of this industry is hindered by increasing treatment costs and high cost associated with R&D. The seropositive rheumatoid arthritis drug market is rather concentrated with few pharmaceutical companies dominating the market through new drug approval.


Intended Audience



  • Seropositive Rheumatoid Arthritis Drug Suppliers

  • Seropositive Rheumatoid Arthritis Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Seropositive Rheumatoid Arthritis Drug Market Segmentation


The seropositive rheumatoid arthritis drug market is segmented on the basis of the drug class, drug, treatment and diagnosis, route of administration, application, and end user.


On the basis of the drug class, the seropositive rheumatoid arthritis drug market is segmented into Non-steroidal anti-inflammatory drug type (NSAID), Steroids, and Disease-modifying anti-rheumatic drug type (DMARDs) and biologic agents.


On the basis of the drug, the seropositive rheumatoid arthritis drug market is segmented into Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Rituxan (rituximab), Actemra (tocilizumab), Orencia (abatacept), and others.


On the basis of the treatment, the seropositive rheumatoid arthritis drug market is segmented into synovectomy, tendon repair, joint fusion, and total joint replacement.


On the basis of the diagnosis, the seropositive rheumatoid arthritis drug market is segmented into C -reactive protein (CRP) Test, CCP, ESR (Erythrocyte Sedimentation Rate) Test and Synovial Fluid Analysis.


On the basis of the route of administration, the seropositive rheumatoid arthritis drug market is segmented into oral, subcutaneous, intravenous, and others.


On the basis of the application, the seropositive rheumatoid arthritis drug market is segmented into medicine, scientific research, and others.


On the basis of the end user, the seropositive rheumatoid arthritis drug market is segmented into hospital, diagnostic centers, ambulatory surgical centers, and others


Seropositive Rheumatoid Arthritis Drug Market Regional Analysis


The seropositive rheumatoid arthritis drug market is segmented into the Americas, Europe, Asia Pacific and the Middle East and Africa.


The Americas dominated the overall market in terms of revenue in 2016 owing to the growing prevalence of arthritis, and rising cases of inflammation in the U.S.


Europe is the second largest rheumatoid market in the globe. The U.K is a major contributor to the European market. As per the National Rheumatoid Arthritis Society (NRAS), it was estimated that approximately 690,000 people suffer from rheumatoid arthritis in the U.K. Moreover, the government bodies are undertaking initiatives for the spreading awareness regarding rheumatoid arthritis is influencing the market growth.


The Asia Pacific is expected to be the fastest growing region, which accounts for more than 60% of the global population. The region has the potential to provide great opportunities for researchers to analyze the pathogenesis, epidemiology, and the factors that influence various manufacturers for expansion and setting up their manufacturing unit in this region.


The Middle East & Africa region contribute the least share of the seropositive rheumatoid arthritis market owing to the low R&D activities, lack of awareness, and poor medical facilities.


Seropositive Rheumatoid Arthritis Drug Market Key Players


Some of key the players in the seropositive rheumatoid arthritis drug market are: 



  • Abbott Laboratories (U.S.) 

  • Johnson & Johnson Limited (U.S.)

  • Novartis AG (Switzerland)

  • Pfizer, Inc. (U.S.)

  • Eli Lilly and Company (U.S.)

  • AbbVie Inc. (U.S.)

  • Bristol-Myers Squibb Company (U.S.)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Amgen (U.S.)

  • Vertex Pharmaceuticals Incorporated (U.S)

  • Sanofi-Aventis (France)

  • AstraZeneca (U.K)

  • Cadila Healthcare Ltd. (India)

  • GlaxoSmithKline Inc. (U.S.)

  • Merck and Co. Inc. (U.S.)

Report Attribute/Metric Details
Market Size 2030  USD 5.52 Billion 2032
Compound Annual Growth Rate (CAGR) 7.78% 2032
Base Year 2023
Market Forecast Period 2024-2032
Historical Data 2022
Market Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, technology, application, and end-users.
Geographies Covered Americas, Europe, Asia Pacific and the Middle East and Africa
Countries Covered China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
Key Companies Profiled Abbott Laboratories (U.S.), Johnson & Johnson Limited (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen (U.S.), Vertex Pharmaceuticals Incorporated (U.S), Sanofi-Aventis (France), AstraZeneca (U.K), Cadila Healthcare Ltd. (India), GlaxoSmithKline Inc. (U.S.), Merck and Co. Inc. (U.S.)
Key Market Opportunities The key market opportunities in the seropositive rheumatoid arthritis drug market include the development of targeted biologics and biosimilars, personalized medicine approaches, and increasing demand for advanced therapies in emerging markets.
Key Market Dynamics Increasing incidence of seropositive rheumatoid arthritis globally drives the demand for effective treatments.


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.